Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05114265 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults | PHASE1 | COMPLETED | 60 | — | — | Feb 15, 2022 | Oct 12, 2022 | Dec 14, 2022 | 1 | New Zealand |
Measured by the incidence of treatment-emergent adverse events
Measured using the cold pressor test
| Arm | Type | Description |
|---|---|---|
| Part 1: Single ascending dose | EXPERIMENTAL | Single dose of oral KUR-101 or oral placebo |
| Part 2: Three-way crossover | EXPERIMENTAL | Single dose of oral KUR-101, oral placebo and oral OxyNorm |
| Name | Type | Description |
|---|---|---|
| KUR-101 | DRUG | Single oral dose of KUR-101 |
| OxyNorm | DRUG | Single oral dose of OxyNorm |
| Placebo | DRUG | Single oral dose of placebo |
Inclusion Criteria: * Healthy male and female subjects; * Between 18 and 55 years of age; * Provide a signed EC-approved consent form; * Generally healthy, in the opinion of the Investigator; * Body Mass Index (BMI) 18 to 32 kg/m\^2; * Using method of contraception; * Willing and able to comply wit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | NA | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | — | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | — | Flozin |